Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Apex Healthcare Bhd's average EBITDA Per Share Growth Rate was -9.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 10.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 15.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Apex Healthcare Bhd was 71.30% per year. The lowest was -2.30% per year. And the median was 9.45% per year.
Apex Healthcare Bhd (XKLS:7090) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Apex Healthcare Bhd 5-Year EBITDA Growth Rate Related Terms
XKLS:7090 vs MCK, COR, CAH: 5-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Apex Healthcare Bhd's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Healthcare Bhd 5-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Apex Healthcare Bhd's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Apex Healthcare Bhd's 5-Year EBITDA Growth Rate falls into.
Apex Healthcare Bhd 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 22.80% mean?
Apex Healthcare Bhd (XKLS:7090) has a 5-Year EBITDA Growth Rate of 22.80% as of Sep. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Apex Healthcare Bhd and its competitors.
Is Apex Healthcare Bhd's 5-Year EBITDA Growth Rate too high?
Apex Healthcare Bhd's current 5-Year EBITDA Growth Rate is 22.80%. Overall, Apex Healthcare Bhd has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Apex Healthcare Bhd's 5-Year EBITDA Growth Rate compare to MCK and COR?
Apex Healthcare Bhd's 5-Year EBITDA Growth Rate of 22.80% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Distribution company?
A good 5-Year EBITDA Growth Rate depends on the Medical Distribution industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Apex Healthcare Bhd and its competitors. Apex Healthcare Bhd's current 5-Year EBITDA Growth Rate is 22.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Healthcare Bhd stock overvalued right now?
Apex Healthcare Bhd (XKLS:7090) has a current 5-Year EBITDA Growth Rate of 22.80%. The stock's GF Value™ is RM2.27, compared to a current price of RM2.61 — trading 15% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 22.80%. Apex Healthcare Bhd's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Apex Healthcare Bhd (XKLS:7090), the current 5-Year EBITDA Growth Rate is 22.80% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Healthcare Bhd (XKLS:7090) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Healthcare Bhd stock appears to be overvalued.
The current stock price of RM2.61 is trading 15% above its estimated GF Value™ of RM2.27.
Key valuation signals for XKLS:7090:
5-Year EBITDA Growth Rate: 22.80%
GF Value™: RM2.27 vs. price of RM2.61 (15% above fair value)
No single metric tells the full story. See the XKLS:7090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Healthcare Bhd is an investment holding company for a group of companies engaged in the development, manufacturing, marketing, and distribution of pharmaceuticals, diagnostics, consumer healthcare products, and orthopedic devices. It has direct operations in Malaysia, Singapore and Others. The company has two manufacturing plants in Melaka and Penang. It has three segments: Manufacturing, Distribution and Corporate. It derives maximum revenue from Malaysia and also has a presence in Singapore and other couintries.
63GF Score
Get the complete analysis for XKLS:7090
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7090 has been successfully added to your 
